VIVUS, Inc. (VVUS) Qsymia Prescriptions Show Gains During Slow Holiday Week (ARNA) (OREX)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/26/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Nasdaq lags on angst over AI spending ahead of earnings reports
Leerink Swann Resumes Arena Pharma (ARNA) at Outperform
February 6, 2013 7:14 AM ESTLeerink Swann initiates coverage on Arena Pharma (NASDAQ: ARNA) with a Outperform rating and $11-$12 valuation range.
The firm comments, "Our due diligence points to a significant transformation occurring in the obesity space, similar in scope to smoking cessation a decade... More
VIVUS (VVUS) Peers Tick Higher Amid Positive Qsymia Data (ARNA) (OREX)
February 1, 2013 8:16 AM ESTVIVUS, Inc. (Nasdaq: VVUS) shares are ticking higher in early trading Friday morning following publication of positive results from a "study concluding that weight loss resulting from treatment with Qsymia (phentermine and topiramate extended-release) capsules CIV led to significant improvements in cholesterol, blood pressure and... More
VIVUS (VVUS) Reports Publication of Signifianct Data from Recent Qsymia Study
February 1, 2013 7:15 AM ESTVIVUS, Inc. (Nasdaq: VVUS) announces the publication of a study concluding that weight loss resulting from treatment with Qsymia (phentermine and topiramate extended-release) capsules CIV led to significant improvements in cholesterol, blood pressure and triglycerides in obese and overweight patients experiencing one or more of these... More
VIVUS (VVUS) Qsymia Prescriptions Jump 140%+ After Free Trial Program Starts
January 7, 2013 6:45 AM ESTVIVUS, Inc. (Nasdaq: VVUS) shares are looking to open higher Monday amid new Qsymia prescription data.
According to Bloomberg, Qsymia prescriptions jumped about 140 percent higher from 5,394 for the four-weeks ended October 26th to 12,978 in the four-week period ended December 21st. The pop came following commencement of its Free Trial program on November 19th through two certified pharmacies.
VIVUS said that a third pharma started the program in late December.
The October data was revised higher from an initial estimate of 4,904 prescriptions.
More color from an 8-K filing made... More
